A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway

被引:4
|
作者
Fu, Jiahui [1 ]
Liang, Peili [2 ]
Zheng, Yingchun [3 ]
Xu, Cailing [1 ]
Xiong, Fu [3 ]
Yang, Fang [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Fetal Med & Prenatal Diag, Guangzhou, Peoples R China
[2] Longgang Dist Matern & Child Healthcare Hosp Shenz, Outpatient & Emergency Management Off, Shenzhen, Peoples R China
[3] Southern Med Univ, Sch Basic Med Sci, Dept Med Genet, Guangzhou, Peoples R China
关键词
Tuberous sclerosis complex; TSC2; Large deletion; PAM signaling pathway; Cardiac rhabdomyoma; Hypomelanotic macules; BRAIN;
D O I
10.1016/j.gene.2024.148312
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background/aim: Tuberous sclerosis complex (TSC) is a multi-system syndrome caused by loss-of-function mutation in TSC1 or TSC2. Most TSC patients present with cardiac rhabdomyoma or cortical tubers during fetal life, and the symptoms are not uniform as their age. The gene products of TSC1/2 are components of the TSC protein complex and are important role in the PI3K/AKT/mTOR (PAM) signaling pathway. Based on three members of a family with variable expressivity, the purpose of this study was to clarify the clinical features of TSC in different age groups and to analyze the genetic characteristics of TSC2 gene. Methods: Clinical exome sequencing and co-segregation were used to identify a three-generation family with four affected individuals. HEK-293T cell model was constructed for subsequent experiments. Quantitative RT-PCR, western blotting, and subcellular localization were used to analyze the expression effect of TSC2 mutation. CCK-8 assay, wound healing assay, and cell cycle analysis were used to analyze the function effect of TSC2 mutation. Result: We identified a TSC family with heterozygous deletion of exon 4 in TSC2 by clinical exon sequencing. Sanger sequencing indicated that the affected individuals have 2541-bp deletion that encompassed exon 4 and adjacent introns. Deletion of exon 4 decreased the TSC2 mRNA and protein levels in HEK-293T cells, and activated the PI3K/AKT/mTOR pathway, thereby altering the cell cycle and promoting cell proliferation and migration. Conclusion: We confirmed the pathogenicity of the large deletion in TSC2 in a three- generations family.. Deletion of exon 4 of TSC2 affected cell proliferation, migration, and cell cycle via abnormal activation of the PAM pathway. This study evaluated the pathogenic effect of deletion of exon 4 of TSC2 and investigated the underlying mechanism.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] The Cardioprotection of the Insulin-Mediated PI3K/Akt/mTOR Signaling Pathway
    Yao, Hong
    Han, Xiangyang
    Han, Xiuzhen
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (06) : 433 - 442
  • [32] Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer
    Akbarzadeh, Maryam
    Mihanfar, Ainaz
    Akbarzadeh, Shabnam
    Yousefi, Bahman
    Majidinia, Maryam
    LIFE SCIENCES, 2021, 285
  • [33] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
    Glaviano, Antonino
    Foo, Aaron S. C.
    Lam, Hiu Y.
    Yap, Kenneth C. H.
    Jacot, William
    Jones, Robert H.
    Eng, Huiyan
    Nair, Madhumathy G.
    Makvandi, Pooyan
    Geoerger, Birgit
    Kulke, Matthew H.
    Baird, Richard D.
    Prabhu, Jyothi S.
    Carbone, Daniela
    Pecoraro, Camilla
    Teh, Daniel B. L.
    Sethi, Gautam
    Cavalieri, Vincenzo
    Lin, Kevin H.
    Javidi-Sharifi, Nathalie R.
    Toska, Eneda
    Davids, Matthew S.
    Brown, Jennifer R.
    Diana, Patrizia
    Stebbing, Justin
    Fruman, David A.
    Kumar, Alan P.
    MOLECULAR CANCER, 2023, 22 (01)
  • [34] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    HaiXia Li
    JianFang Zeng
    Keng Shen
    Archives of Gynecology and Obstetrics, 2014, 290 : 1067 - 1078
  • [35] The Cardioprotection of the Insulin-Mediated PI3K/Akt/mTOR Signaling Pathway
    Hong Yao
    Xiangyang Han
    Xiuzhen Han
    American Journal of Cardiovascular Drugs, 2014, 14 : 433 - 442
  • [36] mTOR/PI3k/Akt SIGNALING PATHWAY IN TUMOR ANGIOGENESIS AND THERAPEUTIC TARGETING
    Mabeta, Peace
    Davis, Paul F.
    Pepper, Michael S.
    ANTICANCER RESEARCH, 2014, 34 (10) : 6042 - 6042
  • [37] The TSC complex links PI3K to mTOR and cancer metabolism
    Manning, Brendan D.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [38] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [39] Targeting PI3K/Akt/mTOR signaling in cancer
    Porta, Camillo
    Paglino, Chiara
    Mosca, Alessandra
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [40] LCN2 SUPPRESSED INFLAMMATION THROUGH PI3K/AKT/MTOR SIGNALING PATHWAY
    Hu, Y.
    Chen, F.
    Huang, C.
    Chen, Z.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S530 - S530